PharmOncology

Ming-Hei Tai
  • 0.0 (0)
  • Medicine
  • Updated weekly

A podcast about pharmacy and oncology

  1. 10 hr ago

    Why current HER2 testing is flawed

    Problems with how we currently test for HER2 and possible future directions. Trastuzumab in endometrial cancer: https://pmc.ncbi.nlm.nih.gov/articles/PMC8792803/Issues with HER2 testing in endometrial cancer: https://www.gynecologiconcology-online.net/article/S0090-8258(25)01072-8/fulltext https://www.mdpi.com/2072-6694/18/12/2009Novel methods of testing for HER2: https://www.nature.com/articles/s41698-026-01365-6

  2. 29 Jul

    Chemotherapy (and especially platinum) Resistance

    Podcast on the changing definition of chemotherapy resistance French small cell lung cancer trial: https://pubmed.ncbi.nlm.nih.gov/32888454/ Platinum resistance in endometrial cancer (Japan): https://pmc.ncbi.nlm.nih.gov/articles/PMC12346239/ 1989 article showing 10% response rates to platinum in platinum resistant ovarian cancer: https://www.nature.com/articles/bjc1989132 Platinum resistant patients may still respond to platinum: https://pubmed.ncbi.nlm.nih.gov/29807697/

  3. 22 Jul

    VIKTORIA-1: Appropriate control arm?

    Thoughts on the FDA's recent approval of gedatolisib https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally

  4. 15 Jul

    What's the difference between the DLBCL second-line regimens?

    Thoughts on all the NCCN preferred second-line DLBCL regimens, other than CAR-T and transplant

  5. 8 Jul

    Why don't we have a pan-tumor drug that targets BRCA mutations?

    The challenges of targeting BRCA mutations in all cancers Tumor lineage shapes BRCA-mediated phenotypes: https://pmc.ncbi.nlm.nih.gov/articles/PMC7048239/

  6. 1 Jul

    DESTINY-Breast11 and Surrogate Endpoints

    Thoughts on using pCR as a surrogate endpoint DESTINY-Breast11: https://pubmed.ncbi.nlm.nih.gov/41130363/ Clinical Cancer Research publication on pCR, EFS and OS: https://aacrjournals.org/clincancerres/article/26/12/2838/82378/Pathologic-Complete-Response-after-Neoadjuvant BMJ publication on pCR, EFS and OS: https://www.bmj.com/content/375/bmj-2021-066381 FDA-sponsored analysis: https://pubmed.ncbi.nlm.nih.gov/24529560/ KATHERINE trial: https://www.nejm.org/doi/full/10.1056/NEJMoa1814017

  7. 24 Jun

    The Fc region of antibodies

    Episode explaining the Fc receptor on antibodies, with some examples! Lessons from TIGIT antibodies: https://pubmed.ncbi.nlm.nih.gov/41389708/

  8. 17 Jun

    CIRCULATE and ctDNA positivity rates

    Discussion on the CIRCULATE trial ASCO CIRCULATE abstract: https://www.asco.org/abstracts-presentations/260542 Real-world experience of circulating tumor DNA testing in resectable colorectal cancer: a Japanese single-institution observational study: https://pmc.ncbi.nlm.nih.gov/articles/PMC12847216/ ASCO GI abstract: Pathologic determinants of ctDNA-shedding in colorectal cancer metastases. https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.183 Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables https://www.sciencedirect.com/science/article/pii/S0169500202001721

See All (14)

About

A podcast about pharmacy and oncology

Information

  • Creator
    Ming-Hei Tai
  • Years Active
    2026
  • Episodes
    14
  • Rating
    Clean
  • Copyright
    © Ming-Hei Tai
  • Show Website
    PharmOncology

You Might Also Like